Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
about
Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infectionGenetic immunization converts the trypanosoma cruzi B-Cell mitogen proline racemase to an effective immunogen.Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.An anionic synthetic sugar containing 6-SO3 -NAcGlc mimics the sulfated cruzipain epitope that plays a central role in immune recognition.Humoral and cellular immune responses to Trypanosoma cruzi-derived paraflagellar rod proteins in patients with Chagas' disease.Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challengeECG detection of murine chagasic cardiomyopathy.Cruzipain Activates Latent TGF-β from Host Cells during T. cruzi Invasion.Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection.Current status and future prospects for a vaccine against American trypanosomiasis.Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.The absence of myocardial calcium-independent phospholipase A2γ results in impaired prostaglandin E2 production and decreased survival in mice with acute Trypanosoma cruzi infection.Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening.Comparison of the infectivity of Trypanosoma cruzi insect-derived metacyclic trypomastigotes after mucosal and cutaneous contaminative challenges.Looking at the proteases from a simple perspective.The role of Toll-like receptors and adaptive immunity in the development of protective or pathological immune response triggered by the Trypanosoma cruzi protozoan.Attenuated Salmonella sp. as a DNA Delivery System for Trypanosoma cruzi Antigens.Differential interleukin-8 and nitric oxide production in epithelial cells induced by mucosally invasive and noninvasive Trypanosoma cruzi trypomastigotes.Perspectives of vaccination in Chagas disease revisited.Depletion of regulatory T cells decreases cardiac parasitosis and inflammation in experimental Chagas disease.Falcipain-1, a Plasmodium falciparum cysteine protease with vaccine potentialType 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.Cruzipain, a major Trypanosoma cruzi antigen, promotes arginase-2 expression and survival of neonatal mouse cardiomyocytes.Sulfates are main targets of immune responses to cruzipain and are involved in heart damage in BALB/c immunized mice.
P2860
Q30452989-210139DC-50EC-4282-8490-A7E5A459D354Q33613943-A815BBB5-37DF-4CF8-AA89-22610487B306Q33656471-4CBC8969-B048-4B39-A746-DBC09439FFECQ34034104-4F54A7A3-61DF-4F31-A426-5F994A0C1906Q34356660-E9FB8C7C-6B6B-42D3-9548-97B0131D259EQ35011455-17D483C0-CCDE-43B8-B24E-35A63D6FD369Q35073839-16BB9B59-F8E2-44C5-8B26-BB155AAC1EFEQ35139381-750E2B62-FE01-4C44-B53B-AC8691D7E721Q35148047-B1E5FC39-5E5C-446C-8F56-B6B58DDEE866Q35621418-D25F6520-06C6-4CEE-84F1-90C7EF9A126FQ36097139-17DE58E8-D57B-42F6-AE56-190781300FB2Q36350576-6B0D593D-92BB-4F53-9626-4B9625FCB156Q36422127-A6EEF5E1-1E7C-4BAF-A9E2-2CE843CBDF61Q36844914-D3EA4526-B022-45CD-B222-E9A24B97CCB9Q36970825-7343AFCA-6A25-4C09-B189-0C0B9A8D9E27Q37309281-0643CEB8-F2A1-4917-BA16-A58A6BB805EFQ37582887-23F55A80-8E33-4BA7-885E-2648D78C9A50Q37675047-A59398DA-559D-43A6-8490-84B29EB2D629Q37848282-CB28CA92-95E6-400E-BC32-C008FEFC2811Q37961913-B7E1E019-FE8D-447E-8394-8BAEDC7E8B43Q38778385-107087C2-41A0-47A2-B843-2F3B4989B0F4Q39863865-3B215544-3123-4B4F-ADD0-815289DB449AQ39945086-64A66C7B-97AD-4C20-8DFA-DF870EA54E38Q41552272-D1806615-719A-4C71-838D-9BE981E22731Q41826054-FDB26FB5-6678-4589-B5AC-8EA2D89291BCQ42957081-896390A2-58E1-4AEA-AD9A-0F71218FD1CDQ44588538-CF2F09D5-DE52-447B-AC4D-09688CBDC5A8Q46808284-EB06939F-1EAB-4A09-9318-E29266B35DA3
P2860
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@ast
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@en
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@nl
type
label
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@ast
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@en
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@nl
prefLabel
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@ast
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@en
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@nl
P2093
P2860
P1476
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
@en
P2093
Anita R Schnapp
Chris S Eickhoff
Daniel F Hoft
Donata Sizemore
Roy Curtiss
P2860
P304
P356
10.1128/IAI.70.9.5065-5074.2002
P407
P577
2002-09-01T00:00:00Z